Literature DB >> 11973456

Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients.

Pia Davidsson1, Ann Westman-Brinkmalm, Carol L Nilsson, Maria Lindbjer, Linda Paulson, Niels Andreasen, Magnus Sjögren, Kaj Blennow.   

Abstract

By comparing the CSF proteome between Alzheimer disease (AD) patients and controls it may be possible to identify proteins that play a role in the disease process and thus to study the pathogenesis of AD. We used mini-gel technology in a two-dimensional electrophoresis procedure, sensitive SYPRO Ruby staining and mass spectrometry for clinical screening of disease-influenced CSF proteins in 15 AD patients and 12 controls. The levels of six proteins and their isoforms, including proapolipoprotein, apolipoprotein E, beta-2 microglobulin, retinol-binding protein, transthyretin, and ubiquitin, were significantly altered in CSF of AD patients. The most prominently altered proteins were the apolipoproteins, especially proapolipoprotein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11973456     DOI: 10.1097/00001756-200204160-00015

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  45 in total

1.  Multiple reaction monitoring assay based on conventional liquid chromatography and electrospray ionization for simultaneous monitoring of multiple cerebrospinal fluid biomarker candidates for Alzheimer's disease.

Authors:  Yong Seok Choi; Kelvin H Lee
Journal:  Arch Pharm Res       Date:  2015-09-24       Impact factor: 4.946

Review 2.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

3.  [Cerebral microdialysis in stroke].

Authors:  C Berger; C Dohmen; M H Maurer; R Graf; S Schwab
Journal:  Nervenarzt       Date:  2004-02       Impact factor: 1.214

Review 4.  Proteomics of human neurodegenerative diseases.

Authors:  Jing Zhang; C Dirk Keene; Catherine Pan; Kathleen S Montine; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2008-10       Impact factor: 3.685

Review 5.  Two-dimensional protein electrophoresis: from molecular pathway discovery to biomarker discovery in neurological disorders.

Authors:  Leila H Choe; Brenda G Werner; Kelvin H Lee
Journal:  NeuroRx       Date:  2006-07

6.  Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective?

Authors:  Xinyi Li; Eliezer Masliah; Natàlia Reixach; Joel N Buxbaum
Journal:  J Neurosci       Date:  2011-08-31       Impact factor: 6.167

Review 7.  Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.

Authors:  Simone Lista; Henrik Zetterberg; Bruno Dubois; Kaj Blennow; Harald Hampel
Journal:  J Neurol       Date:  2014-05-08       Impact factor: 4.849

8.  Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals.

Authors:  Carina Sihlbom; Pia Davidsson; Magnus Sjögren; Lars-Olof Wahlund; Carol L Nilsson
Journal:  Neurochem Res       Date:  2008-02-21       Impact factor: 3.996

9.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.

Authors:  Jing Zhang; Izabela Sokal; Elaine R Peskind; Joseph F Quinn; Joseph Jankovic; Christopher Kenney; Kathryn A Chung; Steven P Millard; John G Nutt; Thomas J Montine
Journal:  Am J Clin Pathol       Date:  2008-04       Impact factor: 2.493

10.  Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke.

Authors:  Laure Allard; Natacha Turck; Pierre R Burkhard; Nadia Walter; Anna Rosell; Marianne Gex-Fabry; Denis F Hochstrasser; Joan Montaner; Jean-Charles Sanchez
Journal:  Biomark Insights       Date:  2007-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.